Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan;51(1):27-38.
doi: 10.1002/eji.202048746. Epub 2020 Dec 23.

Cross talk between human regulatory T cells and antigen-presenting cells: Lessons for clinical applications

Affiliations
Free article
Review

Cross talk between human regulatory T cells and antigen-presenting cells: Lessons for clinical applications

Christine M Wardell et al. Eur J Immunol. 2021 Jan.
Free article

Abstract

Regulatory T cells (Tregs) have a critical role in maintaining self-tolerance and immune homeostasis. There is much interest in using Tregs as a cell therapy to re-establish tolerance in conditions such as inflammatory bowel disease and type 1 diabetes, with many ongoing clinical studies testing the safety and efficacy of this approach. Manufacturing of Tregs for therapy typically involves ex vivo expansion to obtain sufficient cell numbers for infusion and comes with the risk of altering the activity of key biological processes. However, this process also offers an opportunity to tailor Treg function to maximize in vivo activity. In this review, we focus on the roles of antigen-presenting cells (APCs) in the generation and function of Tregs in humans. In addition to stimulating the development of Tregs, APCs activate Tregs and provide signals that induce specialized functional and homing marker expression. Cross talk between Tregs and APCs is a critical, often under-appreciated, aspect of Treg biology, with APCs mediating the key properties of infectious tolerance and bystander suppression. Understanding the biology of human Treg-APC interactions will reveal new ways to optimize Treg-based therapeutic approaches.

Keywords: antigen-presenting cells; homing; immune tolerance; regulatory T cells; suppression.

PubMed Disclaimer

References

    1. Sakaguchi, S., Mikami, N., Wing, J. B., Tanaka, A., Ichiyama, K. and Ohkura, N., Regulatory T Cells and Human Disease. Annual Review of Immunology 2020. 38: 541-566.
    1. Ferreira, L. M. R., Muller, Y. D., Bluestone, J. A. and Tang, Q., Next-generation regulatory T cell therapy. Nature Reviews Drug Discovery 2019. 18: 749-769.
    1. Giganti, G., Atif, M., Mohseni, Y., Mastronicola, D., Grageda, N., Povoleri, G. A. M., Miyara, M. et al. Treg cell therapy: How cell heterogeneity can make the difference.Treg cell therapy: How cell heterogeneity can make the difference. Eur J Immunol 2021. 51: 39-55.
    1. MacDonald, K., Piret, J. and Levings, M., Methods to manufacture regulatory T cells for cell therapy. Clinical & Experimental Immunology 2019. 197: 52-63.
    1. Caramalho, Í., Nunes-Cabaço, H., Foxall, R. B. and Sousa, A. E., Regulatory T-Cell Development in the Human Thymus. Frontiers in Immunology 2015.6.

Publication types

Substances

LinkOut - more resources